867256-77-7

Basic information

• Product Name: 4-CarBoxy-3-fluoroBenzeneBoronicacid,pinacolester
• Synonyms: 4-Carboxy-3-fluorobenzeneboronic acid, pinacol ester 98%;4-Carboxy-3-fluorobenzeneboronicacid,pinacolester98%;2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid;2-fluoro-4-(hydroxy((3-hydroxy-2,3-dimethylbutan-2-yl)oxy)boryl)benzoic acid
• CAS NO: 867256-77-7
• Molecular Formula: C₁₃H₁₆BFO₄
• Molecular Weight: 266.08
• Product Categories: blocks;BoronicAcids;FluoroCompounds
• Mol File: 867256-77-7.mol
• Article Data: 4

Chemical Properties

• Melting Point: 289-295℃
• Boiling Point: 377.6°C at 760 mmHg
• Flash Point: 182.2°C
• Appearance: /
• Density: 1.2g/cm³
• Vapor Pressure: 2.25E-06mmHg at 25°C
• Refractive Index: 1.509
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.16±0.10(Predicted)
• CAS DataBase Reference: 4-CarBoxy-3-fluoroBenzeneBoronicacid,pinacolester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CarBoxy-3-fluoroBenzeneBoronicacid,pinacolester(867256-77-7)
• EPA Substance Registry System: 4-CarBoxy-3-fluoroBenzeneBoronicacid,pinacolester(867256-77-7)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 867256-77-7(Hazardous Substances Data)

Usage

General Description

4-Carboxy-3-fluoroBenzeneBoronicacid, pinacolester, also known as 4-fluoro-3-carboxybenzeneboronic acid pinacol ester, is a chemical compound that is commonly used in the field of organic chemistry. It is a boronic acid derivative with a fluorine atom and a carboxylic acid functionality attached to a benzene ring. The pinacol ester group is a protecting group that can be removed under mild conditions, making this compound useful in organic synthesis. It is often used as a building block in the synthesis of pharmaceuticals and other organic compounds, and its unique structure and reactivity make it valuable in the development of new chemical reactions and processes.

InChI:InChI=1/C13H16BFO4/c1-12(2)13(3,4)19-14(18-12)8-5-6-9(11(16)17)10(15)7-8/h5-7H,1-4H3,(H,16,17)

Upstream product

• 120153-08-4 4-(dihydroxyboranyl)-2-fluorobenzoic acid 
• 76-09-5 2,3-dimethyl-2,3-butane diol 

Downstream Products

• 1492043-12-5 2-(cyclohexylamino)-2-oxo-1-(pyridin-3-yl)ethyl-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1492043-09-0 2-(cyclohexylamino)-1-(2-methoxyphenyl)-2-oxoethyl-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1492043-06-7 2-(cyclohexylamino)-1-(3-methoxyphenyl)-2-oxoethyl-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1492043-02-3 2-(cyclohexylamino)-1-(2-fluorophenyl)-2-oxoethyl-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1492042-99-5 2-(cyclohexylamino)-2-oxo-1-(4-(trifluoromethyl)phenyl)ethyl-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1492042-96-2 2-(cyclohexylamino)-2-oxo-1-phenylethyl-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1205683-48-2 (2,6-dimethyl-morpholin-4-yl)-[2-fluoro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-methanone 

Relevant articles and documents

GLUCOSE SENSITIVE INSULIN DERIVATIVES

The present invention relates to novel insulin derivatives and their use in the treatment or prevention of medical conditions relating to diabetes. The insulin derivatives are glucose sensitive and display glucose-sensitive albumin binding. The invention

NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

[1,2,4]Triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: (I) These compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.